Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

receptor inhibitor Xtandi (enzalutamide) for the same indication.

Generic threat looms to J&J’s blockbuster Zytiga in US

Pfizer’s rival CRPC therapy Xtandi (enzalutamide) could also come under pressure form the entry of low-cost competitors.
Reference price bill tabled in US House and Senate

savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).
Bayer preps filings for new prostate cancer drug

If approved, darolutamide would become the third anti-androgen therapy to be licensed for men with this stage of prostate cancer after Pfizer/Astellas’ Xtandi (enzalutamide) and Johnson &Johnson’s Erleada
EMA starts review of Xtandi in non-metastatic prostate cancer

Reported in February, the study showed that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease spreading or death by 71% compared with hormone therapy
J&J’s Erleada first US drug for non-metastatic prostate cancer

It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been

More from news
Approximately 12 fully matching, plus 45 partially matching documents found.

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Global Business Development Director – Health Education: excellent commission

Engagement Expert, Healthcare Brand Communications, London: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Add my company

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...